BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Antitope Announces Initiation of Antibody Humanization in Collaboration with Kolltan Pharmaceuticals


10/31/2011 9:30:14 AM

Cambridge UK, 31st October 2011 - Antitope Ltd., UK ("Antitope") today announced a research agreement with Kolltan Pharmaceuticals, Inc. ("Kolltan") for the generation of therapeutic monoclonal antibodies for the treatment of cancer. Under the agreement, Antitope will apply its proprietary Composite Human Antibody™ technology for the generation of humanized antibodies.

"We are delighted to be working with Kolltan who we recognize as leaders in developing novel antibody-based cancer therapies by targeting receptor tyrosine kinases," said Dr Matthew Baker, Chief Scientific Officer and co-founder of Antitope. "We are excited about the prospects for Kolltan’s therapeutic antibodies and this collaboration underlies the continuing success of our Composite Human Antibody™ technology."

"Kolltan is pleased to mark an important milestone in its development of novel therapeutic antibodies by collaborating with Antitope in the application of its proprietary humanization procedures,” commented Michael Schmertzler, Chief Executive Officer of Kolltan. “We have been impressed by Antitope’s understanding of Kolltan's commercial needs and look forward to developing the molecule they will provide to us."

About Antitope

Antitope Ltd. is a privately-held Cambridge UK-based biotechnology company specializing in immunogenicity testing and the engineering of therapeutic antibodies/proteins with reduced immunogenicity. Antitope’s proprietary EpiScreen™ technology enables preclinical analysis of the potential for immunogenicity of therapeutic antibodies and proteins. Antitope's proprietary Composite Human Antibody™ technology results in the generation of humanized antibodies devoid of T cell epitopes. Antitope has established multiple commercial relationships with leading biotechnology and pharmaceutical companies worldwide. For further information on Antitope visit www.antitope.co.uk or contact:

Dr Neil Butt

Business Development Director, Antitope Ltd.

Tel: +44 (0)1223 496190

Email: info@antitope.co.uk

About Kolltan Pharmaceuticals

Kolltan Pharmaceuticals, Inc., a privately-held biopharmaceutical company based in New Haven, Connecticut, is developing multiple antibody-based products for the treatment of cancer. These products are based on novel proprietary insights relating to receptor tyrosine kinases (RTKs) arising from the labs of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine. Kolltan was founded in 2007 and has raised $50 million to date. For further information on Kolltan, visit www.kolltan.com



Read at BioSpace.com

Antitope
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES